Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself.
Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets.
Conclusions: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.
(...) - by Barei F. et al., Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1)